Cargando…
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
BACKGROUND: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with poor prognosis of patients with ovarian cancer. AIM: In this study, w...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465006/ https://www.ncbi.nlm.nih.gov/pubmed/26055813 http://dx.doi.org/10.1186/s13048-015-0166-y |